Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Gastric Cancer Market From 2025 To 2029?
The market size for gastric cancer has seen a swift expansion in the latest years. It is predicted to increase from $3.17 billion in 2024 to $3.64 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 14.8%. The previous growth can be traced back to factors such as the burgeoning population of the elderly, amplified healthcare cognizance, augmenting genetic mutations, a surge in the adoption of unhealthy lifestyle habits, and a heightening awareness about cancer.
Expectations are high for swift expansion in the gastric cancer market in the coming years. The market is projected to surge to a value of$6.37 billion by 2029″ with a robust compound annual growth rate (CAGR) of 15.0%. This projected growth within the forecast period can be associated with factors such as the rising obesity problem, growing government initiatives, increased investments in healthcare, escalating demand for oral cancer drugs, and a rising number of specialist facilities for cancer treatment. The forecast period is also expected to witness significant trends including combination chemotherapy, expansion of products, the use of robotic-assisted surgery, targeted therapies, strategic collaborations, and advanced diagnostic tools.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Gastric Cancer Market?
The surge in obesity rates is predicted to fuel the expansion of the gastric cancer market in the future. Obesity, a medical issue marked by excessive fat accumulation in the body, is usually identified by a body mass index (BMI) above 30, resulting in various health problems. The increase in obesity instances can be attributed to factors including poor nutrition, inactivity, sedentary lifestyles, environmental factors, and genetic propensities. Excess body fat, especially abdominal visceral fat, is associated with an increased risk of gastric cancer because obesity leads to persistent inflammation and metabolic disorders, both of which can lead to cancer, thereby increasing the need for gastric cancer therapies. For instance, according to the Switzerland-based World Health Organization’s March 2024 report, approximately one in eight people worldwide were categorized as obese in 2022. The report revealed that 2.5 billion adults aged 18 and over fell into the overweight category, with 890 million suffering from obesity. The data showed that 43% of adults were overweight, and 16% were classified as obese. Additionally, 37 million children below the age of 5 were overweight, and more than 390 million children and adolescents between the ages of 5 and 19 fell into the overweight category, including 160 million living with obesity. As a result of the increasing obesity rates, the gastric cancer market is experiencing a boost in its demand.
Which Key Market Segments Comprise the Gastric Cancer Market and Drive Its Revenue Growth?
The gastric cancermarket covered in this report is segmented –
1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types
2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis
3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments
4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels
Subsegments:
1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma
2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma
3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST
4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3
5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp
Which Areas Are Leading Regions in the Gastric Cancer Market Expansion Across the Globe?
North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theGastric Cancer Market Over the Coming Years?
Market-dominant businesses within the gastric cancer sector are concentrating their efforts on devising innovative and tech-savvy solutions such as companion diagnostic assays. These are tests designed to single out patients most likely to respond positively to a specific therapy based on the detection of certain biomarkers. One such case is of F. Hoffmann-La Roche Ltd., a pharmaceutical company based in Switzerland. They announced in October 2024, the approval of VENTANA CLDN18 (43-14A) RxDx Assay by the U.S. Food and Drug Administration (FDA). This assay is the first immunohistochemistry (IHC) companion diagnostic for measuring CLDN18 protein expression, primarily CLDN18.2, in gastric and gastroesophageal junction (GEJ) adenocarcinoma. It helps identify patients suitable for targeted treatment with VYLOY (zolbetuximab). With the use of the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, this test propels personalized healthcare, paving the way for expanded treatment methods for gastric and GEJ adenocarcinoma.
View the full report here:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report
How Is the Gastric Cancer Market Conceptually Defined?
Gastric cancer is a malignant tumor that originates in the lining of the stomach. It often begins in the mucosa, the innermost layer of the stomach, and can spread to deeper layers, nearby tissues, or distant organs if not treated early. The disease is commonly associated with risk factors such as chronic infection with helicobacter pylori, smoking, excessive alcohol consumption, poor diet, and genetic predisposition.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20797
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model